RAM
CRSP icon

Readystate Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Readystate Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,300
Closed -$1.93M – 786
2024
Q1 		$1.93M Buy
+28,300
New +$2.03M 0.03% 573

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Readystate Asset Management's CRSP Position: Q1 2026 in Review

Readystate Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 20,933 shares worth $996K. The stake represents 0.04% of the portfolio and ranks #230 among its holdings. This is a return to the name: Readystate Asset Management previously reported a position in CRSP as recently as Q3 2024.

Readystate Asset Management first reported a position in CRSP in Q1 2024 and has held it in 3 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Readystate Asset Management held 20,933 shares of CRISPR Therapeutics worth $996K as of Q1 2026.
  • CRISPR Therapeutics was a new Readystate Asset Management position in Q1 2026.
  • CRISPR Therapeutics made up 0.04% of Readystate Asset Management's portfolio in Q1 2026, its #230 holding.
  • Readystate Asset Management first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.